LeMaitre Vascular (LMAT) moved into focus after Conestoga Capital Advisors called it a leading contributor in their first quarter 2026 investor letter, citing 47% operating income growth on mid teens revenue growth.

At a latest share price of $112.40, LeMaitre Vascular has delivered a 5.42% 1 month share price return and a 32.14% 3 month share price return, while the 5 year total shareholder return of 129.47% points to strong long term compounding. The recent pullback of 1.85% on the day still sits within a broader pattern of positive share price momentum, supported by investor attention on its recent operating income performance and expense discipline.

If Conestoga’s positive read on execution has you considering where else consistent operators might be found, it could be worth scanning 18 top founder-led companies

With the shares now just above the latest analyst price target and trading after a strong multi year run, the key question is whether LeMaitre Vascular is now fully valued or if the market is underestimating its future growth potential.

Most Popular Narrative: 1% Overvalued

With LeMaitre Vascular closing at $112.40 against a narrative fair value of $111.22, the current setup rests on relatively tight valuation assumptions.

Strong pipeline of biologics and next-generation products, combined with ongoing regulatory wins, enhances pricing power and product mix; this supports premium pricing and improved gross margins, with successful launches expected to materially contribute to long-term earnings growth.

Want to see what is built into that premium price tag? The narrative leans heavily on sustained double digit organic growth and higher long run margins.

Result: Fair Value of $111.22 (OVERVALUED)

However, there are clear pressure points to watch, including reliance on price increases for growth and execution risks related to international expansion and regulatory approvals.

Next Steps

Given the mixed sentiment in this narrative, it makes sense to move quickly, test the assumptions against the data, and shape your own view by weighing the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you are weighing LeMaitre Vascular, do not stop there. You might miss other opportunities that fit your style just as well or even better.

• Spot potential value ahead of the crowd by checking companies on the screener containing 25 high quality undiscovered gems that match strong fundamentals with under the radar profiles.
• Focus on financial strength first and scan the solid balance sheet and fundamentals stocks screener (44 results) for companies that pair resilient balance sheets with sound business profiles.
• Prioritize stability and peace of mind by reviewing the 72 resilient stocks with low risk scores to see which businesses score well on Simply Wall St's risk checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.